Oberadilol
Oberadilol (CID-3047798) is a Phosphodiesterase III inhibitor, non-selective β-adrenergic receptor blocker, vasodilator and positive inotropic agent. Oberadilol reduces left ventricular end-diastolic volume. Oberadilol is used in research related to chronic congestive heart failure and SARS-CoV-2 infection.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 114856-44-9
- 分子式: C25H30ClN5O3
- 分子量:483.99
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
Adrenergic Receptor アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
[1]|
PDE Ⅲ |
β adrenergic receptor |
体外実験
Oberadilol is a pyridazinone derivative with vasodilatory, β-adrenergic blocking, and type III phosphodiesterase inhibitory activities[1].
Oberadilol reduces left ventricular end-diastolic volume and tends to increase ejection fraction[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
化学情報
-
CAS 番号 114856-44-9
-
分子量 483.99
-
分子式 C25H30ClN5O3
-
SMILES
N#CC1=CC=C(Cl)C=C1OCC(O)CNC(C)(C)CNC2=CC=C(C(C(C)C3)=NNC3=O)C=C2
-
別名
CID-3047798
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
純度とドキュメンテーション
参考文献
[1]. Araki S, et al. Cardiac and hemodynamic effects of TZC-5665, a novel pyridazinone derivative, and its metabolite in humans and dogs. General pharmacology. 1997 Apr;28(4):545-53. [Content Brief]
[3]. Srivastava A, et al. Exploring nature's bounty: identification of Withania somnifera as a promising source of therapeutic agents against COVID-19 by virtual screening and in silico evaluation. J Biomol Struct Dyn. 2022 Mar;40(4):1858-1908. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Keywords
- Oberadilol
- 114856-44-9
- CID-3047798
- CID3047798
- CID 3047798
- Phosphodiesterase (PDE)
- Adrenergic Receptor
- SARS-CoV
- protease inhibitor
- enzyme inhibitor
- chronic congestive heart failure
- GPCR ligand
- COVID-19
- SARS-CoV main protease
- phosphodiesterase-III
- β-adrenergic receptor
- Lipinski's rule of five
- SARS-CoV-2 main protease
- Inhibitor
- inhibitor
- inhibit